AI-generated analysis. Always verify with the original filing.
PTC Therapeutics, Inc. appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director with term expiring at the 2026 annual stockholder meeting. Ms. Chutter, with over 40 years at Morgan Stanley including as Chair of Biotechnology Investment Banking, will receive compensation per the outside director policy including a $50,000 annual retainer and specified equity grants.
Event Type
Disclosure
Mandatory
Variant
8-K
. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 24
. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 2 5 , 2026 issued by PTC Therapeutics, I
Jessica Chutter
Effective: 2026-03-24
filling a vacancy